Table.
Demographics and clinical characteristics of COVID-19 Global Rheumatology Alliance Patient Experience Survey respondents
| Respondents (n=9300) | |
|---|---|
| Age, years | |
| 18–29 | 966 (10·4%) |
| 30–49 | 4658 (50·1%) |
| 50–69 | 3334 (35·8%) |
| ≥70 | 342 (3·7%) |
| Gender | |
| Female | 8375 (90·1%) |
| Male | 893 (9·6%) |
| Non-binary | 32 (0·3%) |
| Race or ethnicity | |
| Arab | 131 (1·4%) |
| Asian | 190 (2·0%) |
| East Asian | 69/190 (36·3%) |
| South Asian | 113/190 (59·5%) |
| West Asian | 8/190 (4·2%) |
| Black | 198 (2·1%) |
| Latin American | 1565 (16·8%) |
| Multiple identities | 455 (4·9%) |
| Native American, Aboriginal, First Nations | 42 (0·5%) |
| Pacific Islander | 10 (0·1%) |
| White | 6273 (67·5%) |
| Other | 162 (1·7%) |
| Unsure | 154 (1·7%) |
| Prefer not to say | 120 (1·3%) |
| WHO region | |
| Region of the Americas | 6113 (65·7%) |
| European region | 2697 (29·0%) |
| Western Pacific region | 253 (2·7%) |
| Eastern Mediterranean region | 131 (1·4%) |
| African region | 84 (0·9%) |
| South-East Asian region | 22 (0·2%) |
| Rheumatic disease diagnosis* | |
| Rheumatoid arthritis | 3636 (39·1%) |
| Systemic lupus erythematosus | 2882 (31·0%) |
| Sjögren's syndrome | 1290 (13·9%) |
| Other connective tissue disease | 1119 (12·0%) |
| Spondyloarthritis (other than psoriatic arthritis) | 1155 (12·4%) |
| Vasculitis | 706 (7·6%) |
| Psoriatic arthritis | 673 (7·2%) |
| Other inflammatory arthritis | 538 (5·8%) |
| Antiphospholipid syndrome | 497 (5·3%) |
| Autoinflammatory disease | 275 (3·0%) |
| Other rheumatic disease | 444 (4·8%) |
| Antirheumatic medications* | |
| Conventional synthetic DMARDs | 6637 (71·4%) |
| Systemic glucocorticoids | 3248 (34·9%) |
| Biologic DMARDs | 2888 (31·1%) |
| Targeted synthetic DMARDs | 299 (3·2%) |
| Other | 154 (1·7%) |
| None | 615 (6·6%) |
| Patient Global Assessment of Disease Activity† | |
| Mean (SD) | 4·5 (2·5) |
| Comorbidities | |
| None | 3258/8923 (36·5%) |
| 1 comorbidity | 2832/8923 (31·7%) |
| 2 comorbidities | 1519/8923 (17·0%) |
| ≥3 comorbidities | 1314/8923 (14·7%) |
| Tobacco smoking status | |
| Current | 943 (10·1%) |
| Past | 2875 (30·9%) |
| Never | 5449 (58·6%) |
| Missing | 33 (0·4%) |
| COVID-19 status and diagnosis method | |
| Yes | 510 (5·5%) |
| Self-diagnosis | 223/510 (43·7%) |
| Physician diagnosis | 179/510 (35·1%) |
| Laboratory test confirmed | 91/510 (17·8%) |
| Not sure | 11/510 (2·2%) |
| Missing | 6/510 (1·2%) |
| No | 8790 (94·5%) |
Data are n (%) or n/N (%), unless otherwise specified. DMARDs=disease-modifying antirheumatic drugs.
*
Participants could indicate more than one rheumatic disease and more than one antirheumatic medication. Categorisations and groupings of comorbidities, rheumatic diseases, and medications can be found in the appendix (p 40). An extended table of the clinical characteristics can be found in the appendix (pp 41–42).
†
n=8962.